Securities code: 300858 securities abbreviation: Beijing Scitop Bio-Tech Co.Ltd(300858) Beijing Scitop Bio-Tech Co.Ltd(300858) record of investor relations activities
No.: 2022-001
Investor relations activities √ specific object research □ analyst meeting
Category □ media interview □ performance briefing
□ press conference □ Roadshow
□ site visit
□ others
Name of participant and Panwen Investment: Wang Ze; BOC Samsung Life: Zhou Jianming; Founder Fubang: Xia Xu; Name of personnel: Pengyang Fund: Wang Yiqin; Huaxia Fund: Wang Shijia; Huian Fund: Xu Zhijie; Oriental Fund: LV Yanchen; Industrial Fund: Jiang Hanyu; Xi Tai Investment: Feng jia’an; Yimi Fund: Liu Zechen; Curious assets: Wan Xuefei; Hongcheng Investment: Xiang Hongbo; Xinyang Fund: Chen Jiecheng; Fengpei Investment: Sun thinking; Orient Securities Company Limited(600958) : Xing Kai, Li Wei; Centennial insurance assets: Du Tianqi; Morgan Stanley Huaxin Fund: Su Xiang; Kaifeng Investment: Fan Huihua; Wuju assets: Wang Xin; Kaiyuan Fund: Wang Jianwei; Red chip investment: Cui Xinyu; Hengyue Fund: Zhang Shanye; Ping An assets: Guo Peng; Kunyi Investment: Zheng ting; Hengtai Securities: Hu Chunyan; Citic Securities Company Limited(600030) : Sun Wenwen; Xingyin Fund: Lin Dehan.
Time: January 7, 2022
Location teleconference
Receptionist of listed company
Deputy general manager and Secretary of the board of directors: Zhang Lingyu
Member name
1、 Introduction to market hot spots and R & D reserves of the company
Helicobacter pylori has a high market heat recently, and Beijing Scitop Bio-Tech Co.Ltd(300858) paid attention to this field in investor relations activities as early as a few years ago. In recent years, the company has introduced the efficacy of Helicobacter pylori against some core strains, conducted scientific experiments and clinical verification, and is applying for relevant patents.
Since its establishment, the company has been based on R & D and relying on its own strain resources
From the library, star strains such as Lactobacillus casei Zhang, Bifidobacterium lactis V9, Lactobacillus plantarum p-8, Bifidobacterium lactis probio-m8 and Lactobacillus rhamnosus probio-m9 from breast milk were screened. The probiotic function of the strain has been verified through large sample clinical trials. In recent years, the company has jointly carried out more than 50 clinical trials with a number of top three hospitals in China, and 29 have been completed. Adjuvant treatment of type two diabetes, prevention of upper respiratory tract infection, relieving asthma symptoms, anti anxiety and anti allergy functions have been confirmed. Starting from 2019, the company began to lay out the probiotic pharmaceutical field and push the probiotic R & D work to a new height.
The theme of “Helicobacter pylori” is highly concerned in the market. On the one hand, the company will continue to carry out this R & D and product design. On the other hand, it will more solidly complete the company’s established R & D objectives. The greatest value of an enterprise is that it can make technological breakthroughs and really make good products, benefit consumers and give back to the society. 2、 Reply to investor questions
1. What is the difference in R & D level between the company’s probiotics and foreign well-known probiotics?
A: compared with foreign well-known probiotic enterprises, the company started late in the research and development of probiotics, but in recent years, the company has caught up quickly and is basically at the same level. Moreover, the samples of clinical trials of the company’s core strains are Chinese or Asian populations, while the samples of clinical trials of foreign probiotics are generally European and American populations. Due to differences in race and eating habits, the company’s probiotics are more suitable for the intestinal tract of Chinese people.
2. Can the performance of the company’s edible probiotic products sector continue to grow high in the future?
A: at present, China’s Probiotic market has formed a large scale and is still growing at a high speed. The market heat and attention are also increasing. As the only listed probiotic company in China, we are confident in the future development of the company’s edible probiotic sector.
Annex list (if any) none
Date: January 9, 2022
